Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms RSS Feed RSS Feeds


Press Release

PharmAkea Announces Successful Completion of a Phase 1 Trial in Healthy Subjects For Its Novel LOXL2 Inhibitor, PAT-1251

Posted on: 22 Aug 17
PharmAkea Announces Successful Completion of a Phase 1 Trial in Healthy Subjects For Its Novel LOXL2 Inhibitor, PAT-1251

PR Newswire

SAN DIEGO, Aug. 22, 2017

SAN DIEGO , Aug. 22, 2017/PRNewswire/ -- PharmAkea, Inc. announced that it has successfully completed a Phase 1 single and multiple ascending dose (SAD/MAD) clinical study with PAT-1251, its novel, small-molecule LOXL2 inhibitor being developed for the treatment of IPF and other fibrotic diseases.

The study results indicate that PAT-1251 was generally well tolerated and a maximum tolerated dose (MTD) was achieved. A proprietary target engagement assay was used successfully to demonstrate that PAT-1251 binds the LOXL2 enzyme in plasma. After successful completion of the 6- and 9-month toxicology studies in Q4 2017, PAT-1251 will be ready to enter Phase 2 clinical development in early 2018.

"Based on its unique mechanism of action, PharmAkea's LOXL2 inhibitor, PAT-1251, has the potential to improve lung function in patients suffering from IPF, a debilitating lung disorder in which novel agents with improved tolerability, efficacy, and long-term safety profiles are needed," said Robert Williamson, CEO of PharmAkea.

The aim of the completed study was to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of oral ascending doses of PAT-1251 in healthy subjects.  The data from these studies will inform the dose selection and study design for a subsequent Phase 2 proof-of-concept study in IPF.

PharmAkea will be presenting a poster on this program at the IPF Summit, on Tuesday, August 22, 2017 in Boston MA.

About PharmAkea, Inc.

PharmAkea is a privately held San Diego-based clinical-stage pharmaceutical company developing novel small molecules against protein targets involved in fibroproliferative diseases. The company has a diversified portfolio, including PAT-1251, a Phase 2 ready LOXL2 inhibitor, for the treatment of IPF, as well as liver and kidney fibrosis, and PAT-409, a Phase 1 ready autotaxin inhibitor for IPF, NASH (nonalcoholic steatohepatitis), PBC (primary biliary cholangitis), scleroderma and chronic kidney disease.  For more information, please visit the Company's website at

Forward-Looking Statements

This press release contains "forward-looking" statements (which are identified by words like "believe," "anticipate," "could," "should," "estimate," "expect," "intend," "plan," "project," "will," "forecast," "budget," "pro forma," and similar terms) that are based on the Company's management's beliefs and assumptions and on information currently available to management. These forward-looking statements include, among others, statements regarding the possible or assumed future results of operations, business strategies, financing plans, competitive position, industry environment, potential growth opportunities and the effects of competition. The Company cautions you that these statements are based on the Company's projections of the future that are subject to known and unknown risks and uncertainties and other factors that may cause the Company's actual results, level of activity, performance or achievements expressed or implied by these forward-looking statements, to differ.


PharmAkea, Inc.
Vanessa L. Jacoby, Vice President, Finance

View original content:

SOURCE PharmAkea, Inc.

PR Newswire

Last updated on: 22/08/2017

Site Map | Privacy & Security | Cookies | Terms and Conditions is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.